Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →Save on this medicine
Same active ingredient — pay up to 80% less
These brands contain the same active ingredient (Dasatinib). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Dasaren এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Dosage of Dasatinib in adult patients: For chronic phase CML in adults, the recommended starting dose of Dasatinib is 100 mg taken by mouth once daily. For accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults, the recommended starting dose is 140 mg taken by mouth once daily. Tablets should be swallowed whole and should not be crushed, cut, or chewed. Patients who take a crushed tablet absorb less of the medicine than those who swallow an intact tablet. Dasatinib can be taken with or without a meal, either in the morning or in the evening. Dosage of Dasatinib in pediatric patients: For children with CML or Ph+ ALL, the recommended starting dose for pediatric patients is based on body weight, as shown in the chart below. The recommended dose should be taken by mouth once daily, with or without food. The dose should be recalculated every 3 months according to changes in body weight, or more often if needed. Body weight 10 kg to less than 20 kg: daily dose 40 mg. Body weight 20 kg to less than 30 kg: daily dose 60 mg. Body weight 30 kg to less than 45 kg: daily dose 70 mg. Body weight at least 45 kg: daily dose 100 mg. Pediatric use: The safety profile of Dasatinib in pediatric subjects was comparable to that reported in studies of adult subjects with chronic phase CML. Bone growth and development in pediatric patients should be monitored.
পার্শ্বপ্রতিক্রিয়া
Dasatinib can cause myelosuppression (suppression of blood cell production), bleeding-related events, fluid retention, cardiovascular events, pulmonary arterial hypertension, QT prolongation, severe skin reactions, tumour lysis syndrome, and effects on growth and development in children.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Myelosuppression: Treatment with Dasaren is associated with severe (NCI CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia. These occur earlier and more often in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML. In patients with chronic phase CML, complete blood counts (CBCs) should be performed every 2 weeks for 12 weeks, then every 3 months thereafter, or as clinically indicated. In patients with advanced phase CML or Ph+ ALL, CBCs should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression is generally reversible and is usually managed by withholding Dasaren temporarily and/or reducing the dose. Bleeding-Related Events: Dasaren can cause serious and fatal bleeding. Concomitant medications that inhibit platelet function, or anticoagulants, may increase the risk of hemorrhage. Fluid Retention: Dasaren may cause fluid retention. Fluid retention events were typically managed by supportive care measures, which may include diuretics or short courses of steroids. Severe pleural effusion may require thoracentesis and oxygen therapy. Dose reduction or treatment interruption should be considered. Cardiovascular Events: Dasaren can cause cardiac dysfunction. Patients should be monitored for signs or symptoms consistent with cardiac dysfunction and treated appropriately. Pulmonary Arterial Hypertension: Dasaren may increase the risk of developing pulmonary arterial hypertension (PAH) in adult and pediatric patients. This may occur at any time after starting treatment, including after more than 1 year of treatment. Manifestations include dyspnea, fatigue, hypoxia, and fluid retention. PAH may be reversible on discontinuation of Dasaren. Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease before starting Dasaren and during treatment. If PAH is confirmed, Dasaren should be permanently discontinued. QT Prolongation: Dasaren may increase the risk of QTc prolongation in patients, including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and those who have received cumulative high-dose anthracycline therapy. Hypokalemia or hypomagnesemia should be corrected before and during Dasaren administration. Severe Dermatologic Reactions: Cases of severe mucocutaneous dermatologic reactions, including Stevens-Johnson syndrome and erythema multiforme, have been reported in patients treated with Dasaren. In patients who experience a severe mucocutaneous reaction during treatment, Dasaren should be discontinued permanently if no other etiology can be identified. Tumor Lysis Syndrome: Tumor lysis syndrome has been reported in patients with resistance to prior Imatinib therapy, primarily in advanced phase disease. Because of the potential for tumor lysis syndrome, adequate hydration should be maintained, uric acid levels should be corrected before starting therapy with Dasaren, and electrolyte levels should be monitored. Patients with advanced stage disease and/or a high tumor burden may be at increased risk and should be monitored more frequently.
নিষেধাজ্ঞা
Dasatinib should not be given to anyone who is known to be allergic (hypersensitive) to Dasatinib or to any other ingredient in the preparation.